The neurodegenerative process in multiple sclerosis and the possible neuroprotective effect of treatment with β-interferon 1a (Avonex)

被引：0
作者：
Davydovskaya M.V. [1 ]
Boiko A.N. [1 ]
Podoprigora A.E. [2 ]
Pronin I.N. [2 ]
Kornienko V.N. [2 ]
Gusev E.I. [1 ]
机构：
[1] N. I. Pirogov Russian National Medical Research University, Moscow
[2] Department of Radiological and Surgical Methods for Diagnosis and Treatment, Academician N. N. Burdenko Research Institute of Neurosurgery, Russian Academy of Medical Sciences, Moscow
来源：
Neuroscience and Behavioral Physiology | 2013年 / 43卷 / 8期
关键词：
interferon β-1a for intramuscular use; multiple sclerosis; neurodegenerative process; proton magnetic resonance spectroscopy;
D O I：
10.1007/s11055-013-9827-8
中图分类号：
学科分类号：
摘要：
The dynamics of changes in the N-acetylaspartate/creatine ratio (NAA/Cr) in brain tissue in patients with multiple sclerosis (MS) were studied by proton multivoxel magnetic resonance spectroscopy (PMRS) to identify relationships between these parameters and the clinical status of patients to assess the potential for using this method in monitoring disease severity and the extent of the neurodegenerative process. The potential neuroprotective effect of treatment with an interferon β-1a formulation for intramuscular administration (IFNβ-1a, Avonex) in patients with remitting MS (rMS) was also studied. A total of 26 patients with rMS took part in the study. Investigations included history-taking, neurological examination with assessment on the EDSS, neuropsychological testing, and dynamic MRI studies using PMRS. A decrease in the NAA/Cr ratio was seen in patients with rMS as compared with healthy subjects. Analysis of the NAA/Cr ratio at one year demonstrated a significant reduction. A negative relationship was found between the NAA/Cr ratio in brain tissue and the levels of neurological and cognitive deficit. Analysis of intramuscular IFNβ-1a treatment of MS demonstrated a stabilizing neuroprotective effect through the one-year treatment period, which may be associated with the effects of this agent on the neurodegenerative process in MS. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：907 / 912
页数：5
相关论文
共 31 条
  • [1] Boiko A.N., Ryabukhina O.V., Davydovskaya M.V., Gusev E.I., Pathogenetic treatment of multiple sclerosis, Multiple Sclerosis, pp. 371-428, (2011)
  • [2] Gusev E.I., Boiko A.N., Multiple sclerosis in the epoch of the wide use of course-modifying agents (MSCMA), Zh. Nevrol. Psikhiat., 109, 2, pp. 4-9, (2009)
  • [3] Davydovskaya M.V., Boiko A.N., Gusev E.I., The neurodegenerative process in multiple sclerosis and possible means of its correction, Zh. Nevrol. Psikhiat., 7 SUPPL. 2, pp. 44-52, (2009)
  • [4] Davydovskaya M.V., Boiko A.N., Gusev E.I., Pathology of the gray matter of the brain in multiple sclerosis, Zh. Nevrol. Psikhiat., 11, pp. 78-84, (2010)
  • [5] Pronin I.N., Belyaeva I.A., Potential of MRI in multiple sclerosis: Diagnosis and prognosis, Multiple Sclerosis and Other Demyelinating Diseases, (2004)
  • [6] Shmidt T.E., Inflammation and neurodegeneration in multiple sclerosis, Nevrol. Zh., 3, pp. 46-52, (2006)
  • [7] Birken D.L., Oldendorf W.H., N-acetyl-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain, Neurosci. Biobehav. Rev., 13, pp. 23-31, (1989)
  • [8] Bitsch A., Bruhn H., Vougioukas V., Et al., Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy, AJNR Am. J. Neuroradiol., 20, pp. 16191-21627, (1999)
  • [9] Dutta R., Trapp B.D., Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis, Prog. Neurobiol., 9, 1, pp. 1-12, (2011)
  • [10] Evangelou N., Konz D., Esiri M.M., Et al., Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis, Brain, 123, 9, pp. 1845-1849, (2000)
1234